Format
Sort by

Send to

Choose Destination

Search results

Items: 5

1.

Amyloid-β 11C-PiB-PET imaging results from 2 randomized bapineuzumab phase 3 AD trials.

Liu E, Schmidt ME, Margolin R, Sperling R, Koeppe R, Mason NS, Klunk WE, Mathis CA, Salloway S, Fox NC, Hill DL, Les AS, Collins P, Gregg KM, Di J, Lu Y, Tudor IC, Wyman BT, Booth K, Broome S, Yuen E, Grundman M, Brashear HR; Bapineuzumab 301 and 302 Clinical Trial Investigators..

Neurology. 2015 Aug 25;85(8):692-700. doi: 10.1212/WNL.0000000000001877. Epub 2015 Jul 24.

2.

Two phase 3 trials of bapineuzumab in mild-to-moderate Alzheimer's disease.

Salloway S, Sperling R, Fox NC, Blennow K, Klunk W, Raskind M, Sabbagh M, Honig LS, Porsteinsson AP, Ferris S, Reichert M, Ketter N, Nejadnik B, Guenzler V, Miloslavsky M, Wang D, Lu Y, Lull J, Tudor IC, Liu E, Grundman M, Yuen E, Black R, Brashear HR; Bapineuzumab 301 and 302 Clinical Trial Investigators..

N Engl J Med. 2014 Jan 23;370(4):322-33. doi: 10.1056/NEJMoa1304839.

3.

Effect of Parameters on Oxychlorination of Tert-Butyl Ethers.

Gaca J, Gackowska A, Belt N.

Toxicol Mech Methods. 2008 Jul;18(6):497-501. Epub 2008 Jun 23.

4.

Sleep problems in fibromyalgia and rheumatoid arthritis compared with the general population.

Belt NK, Kronholm E, Kauppi MJ.

Clin Exp Rheumatol. 2009 Jan-Feb;27(1):35-41.

PMID:
19327227
5.

An aid in pyelography.

BELT N.

J Am Med Assoc. 1954 Jul 17;155(12):1061. No abstract available.

PMID:
13174349

Supplemental Content

Loading ...
Support Center